AI in Healthcare

Today's Stories

1. 1

   Twist Bioscience wins Eli Lilly TuneLab deal, stock up 7.1%

   Twist Bioscience agreed to supply antibody characterization data services to Eli Lilly's AI-driven TuneLab drug discovery platform, and its stock rose 7.1%. The agreement ties Twist Bioscience to AI drug discovery, and analysts see a large AI opportunity in its antibody data business.

   The stock's momentum hinges on whether the rally holds, with $155–157 as first support. Leerink raised its price target to $160 from $120.

2. 2

   Alibaba's RADAR AI hits expert level on abdominal CT

   Alibaba's DAMO Academy released RADAR, a generalist vision-language model trained on over 400,000 contrast-enhanced abdominal CT examinations and 15 million anatomy-aware image–text pairs, learning directly from clinical reports without manual annotation. Alibaba's DAMO Academy says RADAR reaches expert-level performance across both routine and complex clinical tasks, positioning it as a scalable and versatile framework for radiology AI.

   The claim of expert-level performance hinges on whether the model holds up on the external MERLIN test set, which the release provides inference and evaluation tooling for.

3. 3

   Anthropic confirms Bay Area wet biology lab

   Anthropic confirmed to TechCrunch it runs a wet biology lab in the Bay Area where its AI models drive physical experiments, and its head of life sciences, Eric Kauderer-Abrams, said, "We absolutely are doing that today." The lab's focus is fundamental biology, not drug discovery, and Anthropic says it does not want to appear to compete with pharma customers.

   How Anthropic balances these experiments with its warnings that AI could pose catastrophic risks — its own alignment lead put the odds at greater than 10% that AI could exterminate humanity within the next decade.

4. 4

   UnitedHealth sued over nH Predict's 90% error rate in care denials

   A proposed class-action filed November 14, 2023 alleges UnitedHealth and subsidiary NaviHealth used nH Predict, an AI tool the complaint says has a 90% error rate, to deny post-acute care to elderly Medicare Advantage patients. Two families say the denials cost them over $220,000 combined. The complaint argues UnitedHealth knew of the tool's error rate and kept using it because most patients would not challenge denials, leaving alleged wrongful coverage cuts uncorrected.

   A federal magistrate judge has ordered UnitedHealth to produce documentation about nH Predict's role, and discovery remains ongoing as of 2026, so the case hinges on what those records show about the tool's link to actual coverage denials.

5. 5

   AI in Hundreds of Clinical Trials: Successes and Gaps

   Applied Clinical Trials Online reports on lessons drawn from hundreds of clinical trials involving AI, covering its successes, gaps, and opportunities. The findings suggest AI has delivered documented results in clinical trials while leaving open gaps that point to where it could be applied next, though the specifics are seen through the outlet's review.

   The takeaway hinges on which gaps the review identifies as most consequential, since that shapes where clinical-trial teams and sponsors focus next.

6. 6

   Twist Bioscience lands Eli Lilly TuneLab deal, stock up 7.02%

   Twist Bioscience signed an agreement to provide antibody characterization data and services to Eli Lilly's AI/ML TuneLab platform, feeding lab data into Lilly's antibody discovery models. The deal gives Twist a visible role in AI-driven drug discovery, a strategic validation that helped push shares up 7.02% and drew analyst attention.

   Whether the AI-driven opportunity translates into revenue remains the test, with Leerink raising its target to $160 and UBS starting coverage at Neutral with a $144 target.